美國商業資訊

2024-09-23 15:46

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

This 20th edition of the JCA Mauvernay award honored exceptional contributions to cancer research by Dr. Kenichi Yoshida and Dr. Hiroshi Suzuki, reinforcing Debiopharm’s dedication to fostering oncology innovation in Japan

LAUSANNE, Switzerland--()--Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the recognition of the two recipients of the 2024 JCA-Mauvernay Award, marking the 20th edition of this prestigious award. Breakthrough oncology research in Japanese was recognized across two categories, honoring two scientists: Translational Research – Dr. Kenichi Yoshida, and Innovative and/or Disruptive Research – Dr. Hiroshi Suzuki. The award was presented during the 83rd Annual Meeting of the Japanese Cancer Association (JCA) on September 21st at the Fukuoka Convention Center. The winners were honored by Dr. Takashi Kohno, Vice President of JCA.

"At Debiopharm, we remain deeply committed to fostering groundbreaking oncology research that can make a difference in the lives of patients. Our collaboration with Japanese researchers exemplifies how innovation and dedication can drive the development of new therapies. By empowering generations of scientists in Japan, we aim to translate laboratory discoveries into impactful treatments, advancing the field of translational medicine for the benefit of cancer patients worldwide. This reflects our belief that true innovation knows no borders, and by uniting our strengths between Switzerland and Japan, we can bring hope and a cure to those who need it most," stated Thierry Mauvernay, President of Debiopharm.

Dr. Kenichi Yoshida was honored in the Translational Research category for his work at the National Cancer Center Research Institute. Dr. Yoshida’s research has significantly advanced the understanding of somatic mutations in myeloid malignancies, such as Myelodysplastic Syndromes (MDS), including the identification of additional driver genes like RNA-splicing factors, which are now part of the WHO classification for hematological malignancies. His research has also delved into the genetic drivers of Down Syndrome-related myeloid malignancies and explored the role of somatic mutations in normal tissues, revealing early carcinogenic events caused by tobacco smoking. Dr. Yoshida’s ongoing research focuses on driver mutations and therapeutic targets in both cancer and normal tissues using advanced technologies.

Dr. Hiroshi Suzuki was awarded in the Disruptive Research category for his integrative research on super-enhancers, which control cell identity and are linked to cancer pathogenesis. Through a combination of next-generation sequencing (NGS), bioinformatics, and genome/RNA engineering, Dr. Suzuki has deepened the understanding of gene dysregulation in cancer, particularly in the role of microRNA-140 in human skeletal dysplasia. His work in CRISPR/Cas9 genome editing, at the intersection of computational analysis and RNA research, combined with the development of mathematical models, promises to enhance the safety and applicability of genome editing techniques in the future.

The JCA-Mauvernay Award

Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the ‘JCA-Mauvernay Award.’ The award highlights the innovative achievements of Japanese oncology researchers in both fundamental and clinical research. With a total value of CHF 25,000, the award represents the collaborative spirit of scientific discovery between Japan and Switzerland

The positive impact of the JCA Mauvernay Award has been illustrated through the variety of oncology research advances throughout the last 20 years. Notably, the award has encouraged breakthrough research leading to development of second-generation anaplastic lymphoma kinase (ALK) inhibitors (Dr. Mano), a class of anti-cancer drugs targeting an uncommon yet very specific target, the EML4-ALK fusion protein. In some cases, the independent appearance of certain mutations leads to the development of resistance to first-generation ALK inhibitors like crizotinib. Through the identification of the mutated area, second-generation ALK inhibitors like alectinib and loratinib have been developed to increase the survival of non-small cell lung cancer (NSCLC) patients globally.

The award also brought breakthroughs for patients battling adult T-cell leukemia/lymphoma (ATL), an aggressive non-Hodgkin lymphoma with poor prognosis. Through the development of EZH1/2 inhibitors (Dr. Kitabayashi), a class of molecules repressing adult T-cell leukemia/lymphoma (ATL) through their inhibitory activity on either the enhancer of zeste homologue 2 (EZH2) or its homolog EZH1.

Finally, the 10th JCA Mauvernay awarded the discovery of the FGFR2 tyrosine kinase fusion (Ddr. Shibata), a type of mutation prevalent in 10-15% of Cholangiocarcinoma (CCA) cases. This discovery led to the clinical development of FGFR inhibitor, Tasurgratinib, whose market authorization was submitted in 2023 due to the satisfactory overall drug response rate and the manageable safety profile.

Debiopharm's commitment to patients

Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.

For more information, please visit www.debiopharm.com

We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Contacts

Debiopharm
Dawn Bonine
Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11

【你點睇?】特朗普指不排除使用武力奪取格陵蘭及巴拿馬運河,你認為言論會否加劇美國與盟友間的不信任?► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
5
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
6
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
7
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
8
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
9
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
10
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
11
回顧展望-共渡時艱 | 表列機構對今明年本港經濟增長預測
12
回顧展望-樓盡六壬 | 甲廈租金明年料跌9%,華潤頻買民生商場
13
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
14
【FOCUS】「無厘頭」減息釀驚嚇,長債失控顯聯儲失信譽
15
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
16
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
17
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
18
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
19
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
20
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
21
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
22
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
23
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
24
回顧展望-息息相關 | 銀行股明年看好滙控,重組有利減低支出
25
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
26
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
27
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
28
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
29
【FOCUS】華府停擺鬧劇又起,馬斯克功力再進化
30
港股 | 蕭猷華:恒指維持19700點至21000點上落
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet 賞你】賞 MOKO x Cheeky Cheeky「厚」有福氣利是封 及「熊 MEOW 」火柴盒造型年曆卡!

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老